Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Alkermes 2Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Alkermes 2Q

Revenues climb 72%

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Alkermes

2Q Revenues: $124.0 million (+72%)

2Q Loss: $16.7 million (loss of $22.3 million 2Q12)  

YTD Revenues: $276.2 million (+106%)

YTD Earnings: $5.7 million (loss of $35.5 million YTD12)

Comments: Manufacturing and royalty revenues for Risperdal Consta and Invega Sustenna/Xeplion were $50.3 million in the quarter, up 12%, with worldwide end-market sales of $564 million, up 15%. Manufacturing and royalty revenues from Ampyra/Fampyra were $5.0 million, compared to $0.6 million in fiscal 2Q12 and end-market sales by Acorda Therapeutics, in the U.S. were $69.8 million, up 28%. Vivitrolsales were $15.2 million, compared to $9.9 million in fiscal 2Q12. Royalty revenue from Bydureon was $3.3 million, compared to $0.1 million for fiscal 2Q12. Earnings include a one-time charge of $12.1 million related to refinancing the company’s debt in September 2012.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters